arm in Medical Technology

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

... that three additional patients in the pixantrone arm achieved a CR and one additional patient achieved ... p=0.009). No patient in the standard chemotherapy arm achieved a confirmed complete remission at this ... (14 of 70 patients (20.0%) for the pixantrone arm compared to four of 70 patients (5.7%) for the ...

Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment

... achieving a CR/CRu on the pixantrone treatment arm (n=14) had a significant increase in the duration ... (14 out of 70 patients (20.0%) for the pixantrone arm compared to four out of 70 patients (5.7%) for ... with no patients in the standard chemotherapy arm achieving a confirmed complete remission. ...

Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients

... 65%, respectively). Patients on the gemcitabine arm experienced significantly more grade 3/4 toxicities. Additionally, two patients on the gemcitabine arm died due to causes possibly attributed to ... characteristics between both. Patients on arm A were treated with cisplatin (40 mg/m(2)) and ...

VA Studies Advanced Prosthetic Arm

... a three-year study of an advanced artificial arm that easily allows those with severe limb loss to pick up a key or hold a pencil. "This arm is a high-tech example of how VA researchers are ... VA Medical Center. Veterans fitted with the arm will provide feedback to guide engineers in ...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

... efficacy analysis, 36 patients in the control arm and 27 in the treatment arm had clinical events (P=0.14), a non-statistically ... there were 87 clinical events in the control arm and 63 in the ...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

... for 48 weeks. SVR for the low-dose REBETOL arm was 36 percent (n=21/59) compared to 50 percent for a 48-week control arm with PEGINTRON and standard-dose REBETOL plus ... was used by 26 percent of patients in the control arm and 39-51 percent of patients in the boceprevir ...

Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma

... (PFS) was significantly longer in the pixantrone arm (4.7 months vs. 2.6 months, hazard ratio = 0.6; p ... in the pixantrone than in the control arm (1.5% vs. 13.4%). "We were impressed to ... chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard ...

Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone

... chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard ... No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared ... (CR/CRu+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p ...

Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial

... chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard ... with no patients in the standard chemotherapy arm achieving a confirmed complete ... rate (CR/CRu+PR) (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p ...

Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission

... chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard ... No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared ... (CR/uCR+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p ...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

... tract (octreotide LAR arm: n=6, placebo arm n=8), the hematopoetic system (octreotide LAR arm: n=5, placebo arm n=1) and the general health status (fatigue, fever; octreotide LAR arm: n=7, placebo arm n=2). Serious adverse events occurred in 11 ...

Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery

... approximately 25% of patients in the tamoxifen arm selectively crossed over to Femara therapy after the tamoxifen arm was unblinded in 2005. While not statistically ... risk of recurrence, the tamoxifen-only treatment arm was unblinded and approximately one quarter of ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... of death in the VcMP arm, compared with the MP arm (hazard ratio =0.644, p=0.0032; median survival ... the VcMP arm, compared with 8.4 months in the MP arm (p<0.00001). A subset analysis of VcMP ... Millennium. Patients in the VcMP arm of the study received nine 6-week cycles of ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... arm, compared with 60 percent in the VAD arm (p=0.0115). -- Post-induction complete ... arm, compared with 7 percent in the VAD arm (p=0.0035). -- After the first performed ... arm, compared with 22 percent in the VAD arm (p=0.0001). -- After the first performed ASCT, ...

Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months

... a median PFS of >67 months for the Zevalin arm compared to 30.8 in the control arm (HR 0.61[95% CI .41-.91]; p = 0.015). Patients ... a median PFS of 29.6 months for the Zevalin arm compared to 6.7 months in ...

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting

... free survival. Patients in the FCR arm achieved a 30.6-month progression-free survival ... response rate was significantly higher in the FCR arm (70 percent) as compared with the FC arm (58 percent), because of superior ...

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

... weeks. Some patients in the dexamethasone-only arm who failed to achieve a sustained response and ... in the rituximab/dexamethasone combination arm as compared with 36 percent and 39 percent in the ... or sustained response in the dexamethasone-alone arm received the salvage treatment. In this group, ...

GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP

... after just one week, patients in the PROMACTA arm experienced a rise in their median platelet count ... the study, fewer patients in the PROMACTA arm (19 percent) required rescue therapy compared with those in the placebo arm (40 percent, p = 0.001). The overall ...

Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

... survival advantage observed in the OGX-011 arm represents an increase over the median survival ... of 27.5 months for the patients in the OGX-011 arm and 16.9 months for patients in the control arm. ... indicate that patients in the OGX-011 arm have a death rate approximately 40% lower than ...

Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial

... 33 transplant recipients in the recipient-only arm of the study showed significant (p<0.05) ... transplant recipients (33 in the recipient-only arm and 14 in the donor-recipient arm). The ... of CMV-specific immunity in the recipient-only arm as measured by T-cell responses to the two CMV ...

Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint

... chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard ... No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared ... (CR/uCR+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, ...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

... 48-week boceprevir arms or the 48-week control arm of the study. In addition, SVR rates are not yet ... results are not being reported for the boceprevir arm with low-dose REBETOL (n=59) compared to ... Virologic Response (ITT)* Treatment arm All patients No P/R ...

Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults

... -- 79 percent of patients in the PREZISTA/r arm reached an undetectable viral load ( ... 76 percent of patients in the PREZISTA/r arm reached an undetectable viral load ( ... 81 percent of patients in the PREZISTA/r arm reached an undetectable viral load ( ...

Concord Grape Juice Has No Significant Impact on Body Weight

... in the polyphenol-rich 100% Concord grape juice arm did not show significant weight gain whereas ... baseline. Those in the 100% Concord grape juice arm did not show a significant change in appetite, ... in the 100% Concord grape juice arm exhibited a significant reduction in waist ...

TOZAL(R) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration

... the placebo (AREDS-type nutritional supplement) arm lost visual acuity, with an average loss of 1.49 ... receive the standard of care, so no true placebo arm was permitted. Instead, Dr. Cangemi used a widely ... the MIRA study -- including those in the placebo arm -- received AREDS supplements. Patients in the ...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

... Patients in the VELCADE, melphalan and prednisone arm demonstrated a significant survival benefit as ... -- A CR rate of 30 percent in the VcMP arm compared to 4 percent with MP (p<0.001) -- VcMP ... treatment duration was 46 weeks for the VcMP arm compared to 39 weeks for the ...

Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients

... was seen in the PEGINTRON and REBETOL control arm was observed. Treatment discontinuations due to ... 48-week boceprevir arms or the 48-week control arm of the study. Sustained Virologic Response (ITT)* Treatment arm All patients No ...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

... in the pegylated interferon alfa-2b arm compared with observation. The four-year RFS rate ... patients) in the pegylated interferon alfa-2b arm versus 10 percent (60 patients) in the ... (32 patients) in the pegylated interferon alfa-2b arm versus 2 percent (14 patients) in the ...

Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology

... arm; 191 were randomized to the OPAXIO arm with a dosage of 175 mg/m^2, and 96 were randomized to the OPAXIO arm at a dosage of 235 mg/m^2. The OPAXIO dose was ... the comparator arm. More patients in the OPAXIO arm received 6 cycles of treatment (38 percent versus ...

Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma

... disease. The talactoferrin monotherapy single arm trial was conducted at six leading U.S. centers ... trial was an open label, 44-patient, single arm trial conducted at six leading U.S. sites. To ... Avastin in second line RCC patients, the placebo arm had a 4-month PFS rate of 20%, and was chosen ...

ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)

... disease rate in the CoFactor experimental arm compared to a 38.6% stable disease rate and 15.9% ... with 6 patients on the CoFactor experimental arm and 4 patients on the leucovorin control arm. ... were randomized to either the leucovorin control arm or the CoFactor experimental arm, with a ...

Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments

... Adverse events in the RAD001/letrozole treatment arm were manageable. The most frequent grade 3/4 adverse events in the RAD001/letrozole treatment arm were high blood sugar (5%), mouth sores (2%), ... events was 23% in the RAD001/letrozole treatment arm versus 4% in the placebo/letrozole treatment arm. ...

New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens

... of consent.(1) Three patients in the combination arm had an asymptomatic decrease (greater than or ... common adverse events (AEs) in the combination arm versus the monotherapy arm were diarrhea (67 percent vs. 58 percent), rash ...

VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

... remission (CR) rates of 19 percent in the VcD arm as induction therapy and 35 ... data showed 95 percent of patients in the VcD arm were alive at one year. The study was conducted ... were presented by Professor Harousseau. The VcD arm versus the ...

Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment

... at 28 weeks. Patients in the 28-week boceprevir arm who achieve RVR, defined as undetectable virus ... treatment duration of 48 weeks. Patients in any arm of this study with detectable virus at week ... at 36 weeks. Patients in the 36-week boceprevir arm who achieve RVR, defined as undetectable ...

Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma

... for patients on the elesclomol and paclitaxel arm who had one prior chemotherapy showed a trend ... events (Grade 3 or higher) for the combination arm were similar to those seen in the paclitaxel-only arm and included neutropenia, back pain, fatigue and ...

GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)

... in this patient population, with patients on this arm achieving a median progression free survival of ... If patients progressed on the TYKERB monotherapy arm after four weeks of therapy, they could cross ... 1/2 diarrhea higher in the TYKERB + trastuzumab arm (53 percent vs. 41 percent; p=0.03). Two patients ...

PRoFESS(R) Results Announced at XVII European Stroke Conference

... versus 13.1%).(1) In PRoFESS, the AGGRENOX arm had a higher number of hemorrhagic ... were less frequent in the AGGRENOX arm compared to the clopidogrel arm (7.7% and 7.9%, respectively).(1) A post-hoc ...

BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients

... -- 83 percent of patients in the BARACLUDE arm (n=30) and 82 percent of patients in the adefovir arm (n=27) experienced any adverse event. -- Eight ... treatment group. -- No patients in the BARACLUDE arm and one patient in the ...

Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)

... therapy, despite patients in the Pegasys arm overall receiving a significantly higher median ... groups, 39 percent of patients in the Pegasys arm were assigned a higher dose of ribavirin and 10 ... PPV) than patients in the Pegasys combination arm (92 vs. 87 vs. 80 percent, and 81 vs. 83 vs. 74 ...